AORT (Artivion, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by AORT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Jean F Holloway | SVP, General Counsel | Sell | — | — |
| 2026-06-15 | ANDREW M GREEN | SVP, Regulatory and Quality | MIXED | — | — |
| 2026-06-04 | ANTHONY B. SEMEDO | Director | J | — | — |
| 2026-05-20 | Elizabeth A Hoff | Director | A | — | — |
| 2026-05-20 | James Bullock | Director | A | — | — |
| 2026-05-20 | Marna P Borgstrom | Director | A | — | — |
| 2026-05-20 | Jon W Salveson | Director | A | — | — |
| 2026-05-20 | Jeffrey H Burbank | Director | A | — | — |
| 2026-05-20 | THOMAS F ACKERMAN | Director | A | — | — |
| 2026-05-20 | DANIEL J BEVEVINO | Director | A | — | — |
| 2026-05-20 | ANTHONY B. SEMEDO | Director | A | — | — |
| 2026-05-19 | Marna P Borgstrom | Director | A | — | — |
| 2026-03-04 | Amy Horton | VP, Chief Accounting Officer | MIXED | — | — |
| 2026-03-04 | Lance A Berry | EVP, COO, CFO & Treasurer | MIXED | — | — |
| 2026-03-04 | John E Davis | Chief Commercial Officer | MIXED | — | — |
| 2026-03-04 | James P Mackin | President & CEO | MIXED | — | — |
| 2026-03-04 | Marshall S. Stanton | SVP, Clinical & MD Affair | MIXED | — | — |
| 2026-03-04 | Jean F Holloway | SVP, General Counsel | MIXED | — | — |
| 2026-03-03 | Lance A Berry | EVP, COO, CFO & Treasurer | Sell | — | — |
| 2026-03-03 | Marshall S. Stanton | SVP, Clinical & MD Affair | Sell | — | — |
| 2026-03-03 | John E Davis | Chief Commercial Officer | Sell | — | — |
| 2026-03-03 | Amy Horton | VP, Chief Accounting Officer | Sell | — | — |
| 2026-03-03 | Jean F Holloway | SVP, General Counsel | Sell | — | — |
| 2026-03-03 | James P Mackin | President & CEO | Sell | — | — |
| 2026-02-25 | James P Mackin | President & CEO | MIXED | — | — |
| 2026-02-25 | Marshall S. Stanton | SVP, Clinical & MD Affair | Sell | — | — |
| 2026-02-25 | Amy Horton | VP, Chief Accounting Officer | MIXED | — | — |
| 2026-02-25 | Jean F Holloway | SVP, General Counsel | MIXED | — | — |
| 2026-02-25 | John E Davis | Chief Commercial Officer | MIXED | — | — |
| 2026-02-25 | Lance A Berry | EVP, COO, CFO & Treasurer | MIXED | — | — |
| 2025-12-17 | John E Davis | Chief Commercial Officer | Sell | — | — |
| 2025-12-09 | Amy Horton | VP, Chief Accounting Officer | Sell | — | — |
| 2025-12-04 | James P Mackin | President & CEO | MIXED | — | — |
| 2025-12-04 | Jean F Holloway | SVP, General Counsel | Sell | — | — |
| 2025-12-03 | James P Mackin | President & CEO | MIXED | — | — |
| 2025-12-02 | Amy Horton | VP, Chief Accounting Officer | G | — | — |
| 2025-11-24 | Marshall S. Stanton | SVP, Clinical & MD Affair | MIXED | — | — |
| 2025-11-24 | Marshall S. Stanton | SVP, Clinical & MD Affair | MIXED | — | — |
| 2025-11-19 | Elizabeth A Hoff | Director | Sell | — | — |
| 2025-11-18 | Jean F Holloway | SVP, General Counsel | MIXED | — | — |
| 2025-11-18 | John E Davis | Chief Commercial Officer | MIXED | — | — |
| 2025-11-18 | Amy Horton | VP, Chief Accounting Officer | Sell | — | — |
| 2025-11-14 | John E Davis | Chief Commercial Officer | Sell | — | — |
| 2025-11-14 | Jean F Holloway | SVP, General Counsel | Sell | — | — |
| 2025-11-14 | James P Mackin | President & CEO | Sell | — | — |
| 2025-11-14 | Amy Horton | VP, Chief Accounting Officer | Sell | — | — |
| 2025-11-14 | Marshall S. Stanton | SVP, Clinical & MD Affair | Sell | — | — |
| 2025-11-12 | Marshall S. Stanton | SVP, Clinical & MD Affair | Sell | — | — |
| 2025-11-12 | Amy Horton | VP, Chief Accounting Officer | Sell | — | — |
| 2025-11-12 | Jean F Holloway | SVP, General Counsel | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,918,000 | — |
| — | President, CEO and Chairman | 1,128,371 | — |
| — | President & CEO | 965,162 | — |
| — | Executive VP, COO & CFO | 371,178 | — |
| — | Director | 260,755 | — |
| — | Chief Commercial Officer | 230,794 | — |
| — | EVP, COO, CFO & Treasurer | 217,143 | — |
| — | SVP, General Counsel | 194,057 | — |
| — | Director | 159,526 | — |
| — | Director | 157,637 | — |
| — | Director | 157,472 | — |
| — | VP, Chief Accounting Officer | 139,088 | — |
| — | Director | 137,416 | — |
| — | SVP, Regulatory and Quality | 90,259 | — |
| — | Director | 88,250 | — |
| — | Director | 81,955 | — |
| — | Director | 76,223 | — |
| — | SVP, Clinical & MD Affair | 62,246 | — |
| — | Director | 61,372 | — |
| — | Director | 56,664 | — |
| — | VP, Quality | 44,148 | — |
| — | Director | 41,235 | — |
| — | SVP, Operations | 35,102 | — |
| — | Director | 34,765 | — |
| — | VP, Human Resources | 34,116 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AORT quote page; the site-wide leaderboard is on the insider transactions hub.